Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHA:688076)
33.72
+1.23 (3.79%)
At close: Mar 6, 2026
SHA:688076 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | - | 571.39 | 749.08 | 399.96 | 591.88 |
Trading Asset Securities | - | 208 | - | 43.01 | 87.13 |
Cash & Short-Term Investments | 1,081 | 779.39 | 749.08 | 442.98 | 679.01 |
Cash Growth | 38.70% | 4.05% | 69.10% | -34.76% | 353.54% |
Accounts Receivable | - | 539.21 | 297.26 | 251.29 | 143.37 |
Other Receivables | - | 7.92 | 3.27 | 1.19 | 1.05 |
Receivables | - | 547.13 | 300.53 | 252.48 | 144.41 |
Inventory | - | 584.04 | 377.17 | 323.48 | 250.82 |
Other Current Assets | - | 94.97 | 67.98 | 33.53 | 29.86 |
Total Current Assets | - | 2,006 | 1,495 | 1,052 | 1,104 |
Property, Plant & Equipment | - | 1,892 | 1,405 | 988.47 | 706.55 |
Long-Term Investments | - | 215.04 | 117.5 | 94.5 | - |
Goodwill | - | 156.34 | 156.34 | 156.34 | 160.92 |
Other Intangible Assets | - | 108.19 | 112.1 | 98.18 | 88.57 |
Long-Term Deferred Tax Assets | - | 88.27 | 46.65 | 28.13 | 16.63 |
Long-Term Deferred Charges | - | 203.2 | 41.03 | 38.77 | 15.66 |
Other Long-Term Assets | - | 409.4 | 173.84 | 65.44 | 34.46 |
Total Assets | - | 5,078 | 3,547 | 2,522 | 2,127 |
Accounts Payable | - | 159.7 | 141.93 | 87.61 | 72.36 |
Accrued Expenses | - | 149.12 | 86.14 | 48.49 | 43.99 |
Short-Term Debt | - | 1,044 | 546.02 | 318.73 | 77.27 |
Current Portion of Long-Term Debt | - | 117.89 | 40.08 | - | - |
Current Portion of Leases | - | 9.79 | 5.29 | 1.47 | 3.64 |
Current Income Taxes Payable | - | 19.35 | 11.47 | 5.37 | - |
Current Unearned Revenue | - | 61.21 | 8.39 | 6.85 | 26.17 |
Other Current Liabilities | - | 191.83 | 134.01 | 82.8 | 51.96 |
Total Current Liabilities | - | 1,753 | 973.34 | 551.32 | 275.4 |
Long-Term Debt | - | 445.21 | 286.49 | - | - |
Long-Term Leases | - | 25.75 | 17.18 | - | 2.74 |
Long-Term Unearned Revenue | - | 55.99 | 31.46 | 35.32 | 21.74 |
Long-Term Deferred Tax Liabilities | - | 8.61 | 10.16 | 10.77 | 4.26 |
Other Long-Term Liabilities | - | 107.43 | 39.31 | - | 14 |
Total Liabilities | - | 2,396 | 1,358 | 597.41 | 318.14 |
Common Stock | - | 219.78 | 213.18 | 213.18 | 213.18 |
Additional Paid-In Capital | - | 1,598 | 1,341 | 1,319 | 1,318 |
Retained Earnings | - | 792.51 | 495.37 | 374.95 | 277.82 |
Comprehensive Income & Other | - | 50.11 | 120.23 | 3.33 | 2.2 |
Total Common Equity | 3,109 | 2,660 | 2,170 | 1,910 | 1,811 |
Minority Interest | - | 21.95 | 19.04 | 14.66 | -2.61 |
Shareholders' Equity | 3,134 | 2,682 | 2,189 | 1,925 | 1,809 |
Total Liabilities & Equity | - | 5,078 | 3,547 | 2,522 | 2,127 |
Total Debt | 2,584 | 1,642 | 895.07 | 320.19 | 83.65 |
Net Cash (Debt) | -1,503 | -863.06 | -145.98 | 122.79 | 595.36 |
Net Cash Growth | - | - | - | -79.38% | - |
Net Cash Per Share | -4.78 | -2.81 | -0.49 | 0.41 | 2.21 |
Filing Date Shares Outstanding | 316.05 | 307.69 | 298.46 | 298.46 | 298.46 |
Total Common Shares Outstanding | 316.05 | 307.69 | 298.46 | 298.46 | 298.46 |
Working Capital | - | 252.82 | 521.43 | 501.15 | 828.71 |
Book Value Per Share | 9.84 | 8.65 | 7.27 | 6.40 | 6.07 |
Tangible Book Value | 2,779 | 2,396 | 1,902 | 1,656 | 1,562 |
Tangible Book Value Per Share | 8.79 | 7.79 | 6.37 | 5.55 | 5.23 |
Buildings | - | 516.19 | 504.29 | 476.24 | 376.08 |
Machinery | - | 1,603 | 1,123 | 652.13 | 529 |
Construction In Progress | - | 339.92 | 185.96 | 180.11 | 34.85 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.